Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial.

Authors:
Rothermundt C; Hubner R; Ahmad T; Gibbens I; Keyzor C and 3 more

Journal:
Br J Cancer

Publication Year: 2006

DOI:
10.1038/sj.bjc.6602879

PMCID:
PMC2361084

PMID:
16306873

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Br J Cancer

Abbreviation: Br J Cancer

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neoplasms

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of…
Young Han C; Bedia JS; Yang WL and 19 more (2024) - Transparency Score: 3/6
Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and…
Su X; Jin K; Guo Q and 9 more (2024) - Transparency Score: 3/6
Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance…
Mah CY; Nguyen ADT; Niijima T and 12 more (2024) - Transparency Score: 4/6
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relaps…
Hogarty MD; Ziegler DS; Franson A and 15 more (2024) - Transparency Score: 3/6
Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling i…
Mezquita L; Oulhen M; Aberlenc A and 9 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
0/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025